12/4
08:12 am
phvs
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/4
08:12 am
phvs
Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/4
08:05 am
phvs
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Bank of America Corporation from $27.00 to $30.00. They now have a "neutral" rating on the stock.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Bank of America Corporation from $27.00 to $30.00. They now have a "neutral" rating on the stock.
12/3
11:37 pm
phvs
Pharvaris (PHVS) Is Up 5.9% After Phase 3 RAPIDe-3 Win - Has The Bull Case Changed? [Yahoo! Finance]
Medium
Report
Pharvaris (PHVS) Is Up 5.9% After Phase 3 RAPIDe-3 Win - Has The Bull Case Changed? [Yahoo! Finance]
12/3
08:03 pm
phvs
Pharvaris (NASDAQ:PHVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/3
07:02 pm
phvs
Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
12/3
05:48 pm
phvs
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript [Seeking Alpha]
Medium
Report
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript [Seeking Alpha]
12/3
05:05 pm
phvs
Pharvaris (NASDAQ:PHVS) was given a new $38.00 price target on by analysts at Leerink Partners.
Low
Report
Pharvaris (NASDAQ:PHVS) was given a new $38.00 price target on by analysts at Leerink Partners.
12/3
02:19 pm
phvs
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
12/3
10:53 am
phvs
Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment [Yahoo! Finance]
Medium
Report
Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment [Yahoo! Finance]
12/3
06:50 am
phvs
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
High
Report
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
11/22
02:11 am
phvs
Low
Report
11/19
07:01 am
phvs
Pharvaris (NASDAQ:PHVS) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/14
12:31 pm
phvs
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Morgan Stanley from $34.00 to $37.00. They now have an "overweight" rating on the stock.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Morgan Stanley from $34.00 to $37.00. They now have an "overweight" rating on the stock.
11/14
02:40 am
phvs
Pharvaris (PHVS) Is Up 11.3% After Deucrictibant Shows 92% Drop in HAE Attacks and Reports Q3 Loss [Yahoo! Finance]
Medium
Report
Pharvaris (PHVS) Is Up 11.3% After Deucrictibant Shows 92% Drop in HAE Attacks and Reports Q3 Loss [Yahoo! Finance]
11/13
07:45 pm
phvs
Pharvaris (PHVS): Evaluating Valuation Premium After Recent Share Price Momentum [Yahoo! Finance]
Medium
Report
Pharvaris (PHVS): Evaluating Valuation Premium After Recent Share Price Momentum [Yahoo! Finance]
11/13
09:36 am
phvs
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Wedbush from $27.00 to $30.00. They now have an "outperform" rating on the stock.
High
Report
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Wedbush from $27.00 to $30.00. They now have an "outperform" rating on the stock.
11/13
08:11 am
phvs
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
High
Report
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
11/12
06:50 am
phvs
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
11/10
07:10 am
phvs
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting [Yahoo! Finance]
Medium
Report
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting [Yahoo! Finance]
11/10
06:50 am
phvs
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
Medium
Report
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
10/23
06:50 am
phvs
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
Low
Report
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
10/16
06:39 am
phvs
Pharvaris (NASDAQ:PHVS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Low
Report
Pharvaris (NASDAQ:PHVS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
10/15
07:01 am
phvs
Pharvaris (NASDAQ:PHVS) was given a new $60.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
Low
Report
Pharvaris (NASDAQ:PHVS) was given a new $60.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
10/9
08:07 am
phvs
Pharvaris (NASDAQ:PHVS) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating. They now have a $27.00 price target on the stock, up previously from $16.00.
Low
Report
Pharvaris (NASDAQ:PHVS) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating. They now have a $27.00 price target on the stock, up previously from $16.00.